Skyrizi (Risankizumab-rzaa PFS) 75 mg/0.83ml

Skyrizi (risankizumab-rzaa) 75 mg/0.83ml PFS is a prescription injectable used for moderate to severe plaque psoriasis and psoriatic arthritis. Store at 2-8°C to maintain potency. Always follow healthcare provider guidance when using biologics. Short version: Skyrizi 75 mg/0.83ml PFS treats plaque psoriasis and psoriatic arthritis; keep refrigerated between 2-8°C.

Strength

75 mg/0.83ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Abbvie Switzerland

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Skyrizi (risankizumab-rzaa) is a biologic therapy designed to target specific proteins involved in inflammation. It is primarily used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It may also be prescribed for active psoriatic arthritis to reduce joint damage and skin symptoms.

Side Effects

Many patients notice reduced redness, scaling, and thickness of psoriatic plaques after starting Skyrizi. Skin improvement often becomes visible within a few weeks, with continued benefits over time. For psoriatic arthritis, some users report less joint pain and swelling, supporting daily function and mobility.

Precautions & Warnings

Keep Skyrizi refrigerated at 2–8°C and protect from light. Do not freeze or shake vigorously. Before use, allow the prefilled syringe to reach room temperature for about 15–30 minutes. Dispose of used syringes in a sharps container as directed. Always review storage and handling with your healthcare provider.

Avoid Interactions

Skyrizi may interact with other biologics or immunosuppressants, potentially increasing infection risk. Live vaccines should be avoided during treatment. Inform your doctor about all medications, including over-the-counter and herbal products. Regular monitoring may be recommended to assess safety and effectiveness.

Frequently Asked Questions

Skyrizi is used to treat moderate to severe plaque psoriasis and active psoriatic arthritis in adults.

Skyrizi is given as a subcutaneous injection, typically every 12 weeks after initial dosing.

Do not start Skyrizi if you have an active infection; discuss your health status with your healthcare provider.

Store Skyrizi in the refrigerator between 2–8°C and protect it from light.

Skyrizi helps manage symptoms but is not a cure for plaque psoriasis or psoriatic arthritis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.